Cigna Group CEO Brian C. Evanko Reports September 2026 Stock and Option Grants
π Cigna Group CEO Brian C. Evanko filed a Form 4 on September 2, 2026, detailing equity grants made on September 1, 2026.
π He received a restricted stock award of 3,113 shares of common stock issued at no cost with a three-year vesting schedule starting in 2027.
π Evanko now holds direct beneficial ownership of 41,030 shares of Cigna Group common stock following the transaction.
π An employee stock option for 6,716 shares was granted with an exercise price of $281.1325 and a ten-year expiration date.
π¦ The filing confirms Evanko's indirect holdings include approximately 25,614 shares held via a GRAT and 919 shares through the company 401(k) plan.
Bullish Signals
- CEO Brian C. Evanko increased his direct beneficial ownership of common stock to 41,030 shares following the grant of 3,113 restricted shares.
- The receipt of equity awards aligns executive compensation with long-term shareholder value and retention goals for Cigna Group.
Full Analysis
Cigna Group CEO Brian C. Evanko filed a Form 4 on September 2, 2026, disclosing equity awards granted to him on September 1, 2026. The filing details the receipt of 3,113 shares of restricted common stock and an employee stock option for 6,716 shares.
The restricted stock award was issued at no cost with a vesting schedule spanning three equal annual installments beginning September 1, 2027. Following this transaction, Evanko's direct beneficial ownership of Cigna Group common stock stands at 41,030 shares.
Additionally, the CEO holds indirect beneficial interests totaling approximately 26,533 shares through a Grantor Retained Annuity Trust and the company's 401(k) plan. The granted stock option allows for the purchase of shares at an exercise price of $281.1325 per share, expiring in September 2037.